# Allergy Therapeutics to present at the H.C. Wainwright Global Investment Conference

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-to-present-at-the-h.c.wainwright-global-investment-conference/4121065760
- Published: 2022-05-23T07:09:55+01:00
- Author: Giles

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated commercial biotechnology company specialising in allergy vaccines,
has announced that company management will present at the H.C. Wainwright Global
Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

The virtual presentation will be available to registered attendees of the conference
for on-demand viewing beginning May 24, 2022 at 7:00 a.m. ET/12:00 p.m. BST. A replay
of the presentation will be made available under the ‘Investors’ section on Allergy
Therapeutics’ website at [www.allergytherapeutics.com/investors/results-reports-and-presentations/](http://www.allergytherapeutics.com/investors/results-reports-and-presentations/).

Allergy Therapeutics is an international commercial biotechnology company focussed
on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy
vaccines that have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European countries and 
via distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree and house dust
mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in development.

Share on: